Greenleaf Medical AB announced that the company was issued patent #8,642,098 from the U.S. Patent and Trademark Office (USPTO) for their innovation in health science.  The new patent, “Use of plant cell membrane for the treatment of obesity,” issued to Greenleaf Medical AB relates to the use of at least one cell membrane fraction to help retard fat digestion, suppress appetite, body weight and/or lower blood lipids.

Read more

Since winning NutrAward’s ‘Best New Ingredient’ at Nutracon in March 2013, Greenleaf Medical’s Appethyl ™ has been the subject of five new successful clinical trials. These five human studies and two animal trials have affirmed both the appetite suppression and weight loss effects found in the original pilot trials.

Read more

Greenleaf Medical celebrated the GRAMMY Awards nominees and presenters as the official sponsor of the Red Carpet Events LA Luxury Gift Lounge by gifting celebrities with the award-winning appetite suppressant, Appethyl™.

Read more

Greenleaf Medical’s continuous study of patented spinach extract, Appethyl™, has shown this appetite suppressant supplement to also have prebiotic effects.

Read more

Greenleaf Medical AB is pleased to announce that its appetite suppressant supplement Appethyl™, has been chosen as one of three finalists for Best New Ingredient at the 15th annual 2013 NutrAwards. A winner will be announced at the 2013 Nutracon event held in Anaheim, California on Wednesday, March 6, 2013.

Read more

Green Leaf Medical AB licensed all IP/patent rights linked to the production and use of the new appetite-reducing substance thylakoids so that it can now be added to natural weight management products. Thylakoids is concentrated from spinach, and the research, as well as the technology used for the work with thylakoids, was developed by professor Charlotte Erlanson-Albertsson, department of experimental medical science, and professor Per-Åke Albertsson, department of biochemistry, Lund University, Sweden.

Read more